- Trial phase
- Phase 1
- Time to market
- Likely several years away. The drug is still in Phase 1 dose expansion with no registrational trial initiated. If Phase 1 data support advancement, Phase 2/3 trials would need to be completed before any regulatory filing, likely 2028-2030 at the earliest.
- Why 2/10
- ABBV-2001 is a Phase 1 asset with no scheduled PDUFA, pivotal readout, or other hard binary catalyst in the next ~12 months. It is a small part of AbbVie's massive pipeline, so even data readouts would have negligible impact on the stock.
Watch for Phase 1 dose-expansion data from the TRIgnite-1 study (NCT05862012), which could come at a medical meeting in 2027. Positive data would support advancement to Phase 2/3, but ABBV-2001 is a small pipeline component for AbbVie, so even strong readouts are unlikely to move the stock materially. The more relevant near-term catalyst for AbbVie's multiple myeloma franchise is the etentamig (ABBV-383) BLA, submitted to the FDA on October 27, 2026.
Price Chart
Executive Summary
ABBV-2001 (ISB 2001) is a first-in-class trispecific T-cell engager targeting CD38, BCMA, and CD3, being developed by AbbVie for relapsed/refractory multiple myeloma. AbbVie licensed the drug from Ichnos Glenmark Innovation in July 2025 for $700M upfront (up to $1.925B total). It is currently in Phase 1 dose expansion (TRIgnite-1 study) and has shown promising early data: a 79% overall response rate and 30% complete response rate across active dose levels in heavily pretreated patients, including activity after prior BCMA-targeted therapy. The drug has received FDA Orphan Drug and Fast Track designations. However, it remains an early-stage asset years from potential approval, and for AbbVie (a ~$295B market cap company), it is a very small part of a large pipeline.
How It Works
ABBV-2001 is a trispecific antibody (a type of engineered immune protein) that grabs T-cells (the immune system's killer cells) with one arm and simultaneously latches onto two different targets on myeloma cancer cells (BCMA and CD38). This brings the T-cells close to the cancer cells so they can destroy them. By targeting two cancer-cell markers at once, the drug aims to work even when cancer cells have stopped expressing one of the targets, potentially overcoming resistance to existing bispecific antibody therapies.
Trial Status
ABBV-2001 is being studied in the TRIgnite-1 Phase 1 first-in-human trial (NCT05862012), which completed dose escalation (Part 1) and is now in Part 2 dose expansion to confirm safety and select the recommended Phase 2 dose. AbbVie is also running a separate Phase 1 combination study (M25-059) testing ABBV-2001 alongside its BCMA bispecific etentamig (ABBV-383). Phase 1 dose-escalation data presented at ASCO 2025 (24 patients) showed a 79% ORR and 30% CR/sCR rate with no dose-limiting toxicities. Updated data at IMS 2026 showed a 64% rate of VGPR or better with low rates of CRS and ICANS.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 dose-expansion data from TRIgnite-1 study (likely at a medical meeting in 2027)
- Potential initiation of Phase 2/3 registrational study if dose expansion confirms the recommended dose and safety profile
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report